GlassScriptPhysician profile
Iqra Choudary
NPI 1346529971
$6,237.40
in general payments reported to CMS, 2019-2025
29 companies · $2,190 in 2025
The $2,190 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $504 · 2020: $185 · 2021: $310 · 2022: $216 · 2023: $230 · 2024: $2,603 · 2025: $2,190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,100 · Honoraria: $1,500 · Travel and Lodging: $726 · Food and Beverage: $676 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,100.00 |
| Honoraria | $1,500.00 |
| Travel and Lodging | $726.43 |
| Food and Beverage | $676.00 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $2,482.63 | 2024 | Monoferric |
| Pfizer INC. | $2,166.80 | 2019-2025 | |
| Lilly USA, LLC | $232.09 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $153.69 | 2019-2023 | Opdivo |
| Beigene USA, INC. | $150.00 | 2023 | Brukinsa |
| Seagen INC. | $116.43 | 2019-2021 | |
| Pharmacyclics LLC, An Abbvie Company | $109.39 | 2019-2021 | |
| Janssen Biotech, INC. | $107.97 | 2019-2020 | |
| Genmab U.S., INC. | $101.40 | 2024 | Epkinly |
| Incyte Corporation | $99.95 | 2021 | |
| Novartis Pharmaceuticals Corporation | $93.48 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $54.18 | 2019 | |
| Noah Medical Corporation | $42.51 | 2025 | Galaxy |
| Puma Biotechnology, INC. | $34.23 | 2019 | |
| Celgene Corporation | $30.45 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adaptive Biotechnologies Corporation | $27.27 | 2025 | Clonoseq |
| Astrazeneca Pharmaceuticals LP | $22.66 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.43 | 2020 | |
| Genentech USA, INC. | $20.23 | 2021 | |
| Genzyme Corporation | $20.05 | 2019 | |
| Aveo Pharmaceuticals, INC. | $20.00 | 2025 | |
| Tempus Ai, INC | $18.80 | 2024 | |
| Exelixis INC. | $17.71 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $17.69 | 2019 | |
| Amgen INC. | $17.23 | 2020 | |
| Abbvie INC. | $16.93 | 2019 | |
| Clovis Oncology, INC. | $15.04 | 2019 | |
| Foundation Medicine, INC. | $13.60 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.56 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Iqra Choudary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.